prednisone has been researched along with B Virus Infection in 43 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The proportion of intravenous drug abusers (IVDA) in HIV-HD (38%) is higher than in French HIV-infected population as a whole (20." | 3.78 | Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors. ( Andrieu, JM; Brice, P; Colonna, P; Gastaut, JA; Lévy, R; Raphaël, M; Taillan, B; Tourani, JM, 1995) |
| "The immunosuppressive effects of three herpesviruses--cytomegalovirus (CMV), Epstein-Barr virus (EBV), and herpes simplex virus (HSV)--were assessed in 29 renal transplant recipients treated with cyclosporine and prednisone." | 3.67 | Effect of herpesvirus infections on T-lymphocyte subpopulations and blastogenic responses in renal transplant recipients receiving cyclosporine. ( DeBiasio, RL; Hakala, TR; Hamoudi, WH; Liebert, M; Rabin, B; Rinaldo, CR, 1986) |
| "A case of primary intracerebral Hodgkin's disease (HD) without dural attachment in a 54-year-old immunocompetent patient is described." | 2.40 | Primary intracerebral Hodgkin's disease: report of a case with Epstein-Barr virus association and review of the literature. ( Bendszus, M; Klein, R; Kreipe, H; Müllges, W; Roggendorf, W; Woydt, M, 1999) |
| "The main cause of Bell's palsy is probably reactivation of latent herpes viruses." | 1.33 | [Arguments favouring the pharmacotherapy of Bells' palsy]. ( de Ru, JA; Hordijk, GJ; van Benthem, PP, 2005) |
| " Inflammation was stabilized, and steroid dosage could be significantly reduced." | 1.32 | Nonnecrotizing herpetic retinopathies masquerading as severe posterior uveitis. ( Bodaghi, B; Cassoux, N; Fardeau, C; LeHoang, P; Rozenberg, F, 2003) |
| "Lymphocytic interstitial pneumonitis (LIP) is characterized by diffuse bilateral pulmonary infiltrations in both lower lobes." | 1.31 | Lymphocytic interstitial pneumonitis associated with Epstein-Barr virus in Systemic Lupus Erythematosus and Sjögren's Syndrome. Complete remission with corticosteriod and cyclophosphamide. ( Choi, SJ; Kim, ES; Lee, HK; Ok, KS; Yum, HK, 2002) |
| "We describe two cases of Hodgkin's disease after heart and heart/lung transplants respectively." | 1.29 | Hodgkin's disease after cardiac transplant: a report of two cases. ( Hood, IM; Mahendra, P; Marcus, RE; McNeil, K, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (30.23) | 18.7374 |
| 1990's | 12 (27.91) | 18.2507 |
| 2000's | 11 (25.58) | 29.6817 |
| 2010's | 6 (13.95) | 24.3611 |
| 2020's | 1 (2.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ramos, JC | 1 |
| Sparano, JA | 1 |
| Chadburn, A | 1 |
| Reid, EG | 1 |
| Ambinder, RF | 1 |
| Siegel, ER | 1 |
| Moore, PC | 1 |
| Rubinstein, PG | 1 |
| Durand, CM | 1 |
| Cesarman, E | 1 |
| Aboulafia, D | 1 |
| Baiocchi, R | 1 |
| Ratner, L | 1 |
| Kaplan, L | 1 |
| Capoferri, AA | 1 |
| Lee, JY | 1 |
| Mitsuyasu, R | 1 |
| Noy, A | 1 |
| Shah, NN | 1 |
| Harrison, N | 1 |
| Stonecypher, M | 1 |
| Frank, D | 1 |
| Amorosa, V | 1 |
| Svoboda, J | 1 |
| Melikyan, AL | 1 |
| Egorova, EK | 1 |
| Julhakyan, HL | 1 |
| Kovrigina, AL | 1 |
| Savchenko, VG | 1 |
| Shin, J | 1 |
| Lee, JO | 1 |
| Choe, JY | 1 |
| Bang, SM | 1 |
| Lee, JS | 1 |
| Takahashi, T | 1 |
| Hangaishi, A | 1 |
| Yamamoto, G | 1 |
| Ichikawa, M | 1 |
| Imai, Y | 1 |
| Kurokawa, M | 1 |
| Stingaciu, S | 1 |
| Ticchioni, M | 1 |
| Sudaka, I | 1 |
| Haudebourg, J | 1 |
| Mounier, N | 1 |
| Oh, J | 1 |
| Yoon, H | 1 |
| Shin, DK | 1 |
| Jang, MJ | 1 |
| Kim, GI | 1 |
| Chong, SY | 1 |
| Oh, D | 1 |
| Yum, HK | 1 |
| Kim, ES | 1 |
| Ok, KS | 1 |
| Lee, HK | 1 |
| Choi, SJ | 1 |
| Du, MQ | 1 |
| Diss, TC | 1 |
| Liu, H | 1 |
| Ye, H | 1 |
| Hamoudi, RA | 1 |
| Cabeçadas, J | 1 |
| Dong, HY | 1 |
| Harris, NL | 1 |
| Chan, JK | 1 |
| Rees, JW | 1 |
| Dogan, A | 1 |
| Isaacson, PG | 1 |
| Boulanger, E | 2 |
| Brière, J | 1 |
| Gaulard, P | 1 |
| Droz, D | 1 |
| Oksenhendler, E | 2 |
| Bodaghi, B | 1 |
| Rozenberg, F | 1 |
| Cassoux, N | 1 |
| Fardeau, C | 1 |
| LeHoang, P | 1 |
| CHEEVER, AW | 1 |
| VALSAMIS, MP | 1 |
| RABSON, AS | 1 |
| Yamamoto, Y | 1 |
| Teruya, K | 1 |
| Katano, H | 1 |
| Niino, H | 1 |
| Yasuoka, A | 1 |
| Kimura, S | 1 |
| Oka, S | 1 |
| Huang, Q | 1 |
| Chang, KL | 1 |
| Gaal, KK | 1 |
| Weiss, LM | 1 |
| Norin, S | 1 |
| Kimby, E | 1 |
| Ericzon, BG | 1 |
| Christensson, B | 1 |
| Sander, B | 1 |
| Söderdahl, G | 1 |
| Hägglund, H | 1 |
| de Ru, JA | 1 |
| van Benthem, PP | 1 |
| Hordijk, GJ | 1 |
| Chen, YB | 1 |
| Rahemtullah, A | 1 |
| Hochberg, E | 1 |
| Starzl, TE | 1 |
| Nalesnik, MA | 1 |
| Porter, KA | 1 |
| Ho, M | 1 |
| Iwatsuki, S | 1 |
| Griffith, BP | 1 |
| Rosenthal, JT | 1 |
| Hakala, TR | 2 |
| Shaw, BW | 1 |
| Hardesty, RL | 1 |
| Crawford, DH | 1 |
| Edwards, JM | 1 |
| Sweny, P | 1 |
| Hoffbrand, AV | 1 |
| Janossy, G | 1 |
| Adour, KK | 1 |
| Wilcox, RD | 1 |
| Byl, FM | 1 |
| O'Riordan, JM | 1 |
| Molloy, K | 1 |
| O'Briain, DS | 1 |
| Corbally, N | 1 |
| Devaney, D | 1 |
| McShane, D | 1 |
| Considine, N | 1 |
| McCann, SR | 1 |
| Lévy, R | 1 |
| Colonna, P | 1 |
| Tourani, JM | 1 |
| Gastaut, JA | 1 |
| Brice, P | 1 |
| Raphaël, M | 1 |
| Taillan, B | 1 |
| Andrieu, JM | 1 |
| Tirelli, U | 1 |
| Errante, D | 1 |
| Dolcetti, R | 1 |
| Gloghini, A | 1 |
| Serraino, D | 1 |
| Vaccher, E | 1 |
| Franceschi, S | 1 |
| Boiocchi, M | 1 |
| Carbone, A | 1 |
| Hayashi, T | 1 |
| Yamabe, H | 1 |
| Haga, H | 1 |
| Akasaka, T | 1 |
| Kadowaki, N | 1 |
| Ohno, H | 1 |
| Okuma, M | 1 |
| Fukuhara, S | 1 |
| Wilson, WH | 1 |
| Kingma, DW | 1 |
| Raffeld, M | 1 |
| Wittes, RE | 1 |
| Jaffe, ES | 1 |
| Keiser, P | 1 |
| Jockus, J | 1 |
| Horton, H | 1 |
| Smith, JW | 1 |
| Hood, IM | 1 |
| Mahendra, P | 1 |
| McNeil, K | 1 |
| Marcus, RE | 1 |
| Newell, KA | 1 |
| Alonso, EM | 1 |
| Kelly, SM | 1 |
| Rubin, CM | 1 |
| Thistlethwaite, JR | 1 |
| Whitington, PF | 1 |
| Mookerjee, BP | 1 |
| Vogelsang, G | 1 |
| McCarthy, M | 1 |
| Ramage, J | 1 |
| McNair, A | 1 |
| Gane, E | 1 |
| Portmann, B | 1 |
| Pagliuca, A | 1 |
| Rela, M | 1 |
| Heaton, N | 1 |
| Mufti, GJ | 1 |
| Williams, R | 1 |
| Klein, R | 1 |
| Müllges, W | 1 |
| Bendszus, M | 1 |
| Woydt, M | 1 |
| Kreipe, H | 1 |
| Roggendorf, W | 1 |
| Mamzer-Bruneel, MF | 1 |
| Lomé, C | 1 |
| Morelon, E | 1 |
| Levy, V | 1 |
| Bourquelot, P | 1 |
| Jacobs, F | 1 |
| Gessain, A | 1 |
| Mac Intyre, E | 1 |
| Brousse, N | 1 |
| Kreis, H | 1 |
| Hermine, O | 1 |
| Agbalika, F | 1 |
| Maarek, O | 1 |
| Daniel, MT | 1 |
| Grollet, L | 1 |
| Molina, JM | 1 |
| Sigaux, F | 1 |
| Britz, M | 1 |
| Sibulkin, D | 1 |
| Melosky, B | 1 |
| Karim, M | 1 |
| Chui, A | 1 |
| McBride, M | 1 |
| Cameron, EC | 1 |
| Yeung, CK | 1 |
| Landsberg, D | 1 |
| Shackleton, C | 1 |
| Keown, PA | 1 |
| Rinaldo, CR | 1 |
| DeBiasio, RL | 1 |
| Hamoudi, WH | 1 |
| Rabin, B | 1 |
| Liebert, M | 1 |
| Fierer, J | 1 |
| Bazely, P | 1 |
| Braude, AI | 1 |
| Spencer, ES | 1 |
| Andersen, HK | 1 |
| Katzenellenbogen, I | 1 |
| Frumkin, A | 1 |
| Simone, JV | 1 |
| Holland, E | 1 |
| Johnson, W | 1 |
| Pien, FD | 1 |
| Smith, TF | 1 |
| Anderson, CF | 1 |
| Webel, ML | 1 |
| Taswell, HF | 1 |
| Orenstein, JM | 1 |
| Castadot, MJ | 1 |
| Wilens, SL | 1 |
| Arora, KK | 1 |
| Karalakulasingam, R | 1 |
| Raff, MJ | 1 |
| Martin, DG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma[NCT01193842] | Phase 1/Phase 2 | 107 participants (Actual) | Interventional | 2010-10-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The percentage of participants surviving without events (relapse or death) one year after starting treatment. (NCT01193842)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Phase II: VR-DA-EPOCH | 75.6 |
| Phase II: DA-R-EPOCH | 82.2 |
The percentage of participants surviving one year after starting treatment. (NCT01193842)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Phase II: VR-DA-EPOCH | 77.6 |
| Phase II: DA-R-EPOCH | 86.7 |
"Percentage of participants with complete response as assessed by Response Evaluation Criteria in Solid Tumors (Phase II) according to treatment arm. Participants are planned to be treated for a total of 6 cycles (21 day cycle length). Participants with CR after Cycle 4 will receive two additional cycles of chemotherapy and complete 6 cycles of chemotherapy. Participants who achieve a partial response (PR) only after Cycle 4 may continue on protocol therapy or they may be removed from the study at the AMC discretion of the physician (local Principal Investigator). Participants with stable disease after 4 cycles (i.e., who did not achieve at least a PR) or progressive disease at any time will be removed from study.~In phase II, there are two arms: Vorinostat RPTD+rituximab-DA-EPOCH arm (VR-DA-EPOCH) and Rituximab-DA-EPOCH arm (DA-R-EPOCH)." (NCT01193842)
Timeframe: Up to 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Phase II: VR-DA-EPOCH | 67.5 |
| Phase II: DA-R-EPOCH | 76.2 |
Recommended phase II dose of vorinostat is defined as the dose level at which 0/6 or 1/6 subjects experience dose limiting toxicity (DLT) with the next higher dose having at least 2/3 or 2/6 subjects encountering DLT (Phase I). Toxicities will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Using a 3+3 design, the recommended phase II dose is defined as the level at which 0/6 or 1/6 patients experiences at dose-limiting toxicity in the first cycle. (NCT01193842)
Timeframe: 21 days
| Intervention | Mg per day of Vorinostat (Number) |
|---|---|
| Phase I: VR-DA-EPOCH | 300 |
Differences from baseline (specified follow-up assessment minus baseline) in absolute CD8 counts. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | cells/mm^3 (Median) | |||
|---|---|---|---|---|
| End of cycle 2 | Treatment discontinuation | 6-month follow-up | 12-month follow-up | |
| Phase I: VR-CHOP, Dose Level 1 | -172 | -81 | -16 | 128 |
| Phase I: VR-DA-EPOCH, Dose Level 1 | 35.5 | -164.5 | -56 | 604 |
| Phase I: VR-DA-EPOCH, Dose Level 2 | -115 | 211 | 275 | 154 |
Differences from baseline (specified follow-up assessment minus baseline) in HIV viral load. Undetectable viral load results were treated as 0 values. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | copies per milliliter (Median) | |||
|---|---|---|---|---|
| End of cycle 2 | Treatment discontinuation | 6-month follow-up | 12-month follow-up | |
| Phase I: VR-CHOP, Dose Level 1 | 28 | 0 | 0 | 0 |
| Phase I: VR-DA-EPOCH, Dose Level 1 | -14518 | -4517 | -55116 | 0 |
| Phase I: VR-DA-EPOCH, Dose Level 2 | -12.5 | 0 | 0 | 0 |
Differences from baseline (specified follow-up assessment minus baseline) in absolute CD4 counts. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | cell/mm^3 (Median) | |||
|---|---|---|---|---|
| End of cycle 2 | Treatment discontinuation | 6-month follow-up | 12-month follow-up | |
| Phase I: VR-CHOP, Dose Level 1 | -218 | -190 | -175 | -84 |
| Phase I: VR-DA-EPOCH, Dose Level 1 | 92 | -39 | 76 | 169 |
| Phase I: VR-DA-EPOCH, Dose Level 2 | -9 | -29 | 31 | 31 |
Differences from baseline (specified follow-up assessment minus baseline) in EBV viral load. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | IU/mL (Median) | |||
|---|---|---|---|---|
| End of Cycle 2 | At treatment discontinuation | 6-month follow-up | 12-month follow-up | |
| Phase I: VR-DA-EPOCH, Dose Level 1 | 0 | 0 | 0 | 0 |
| Phase I: VR-DA-EPOCH, Dose Level 2 | -2436.1 | -1.92 | -1.92 | -1.15 |
| Phase II, DA-R-EPOCH | 0 | -0.28 | 0 | -2.7 |
| Phase II, VR-DA-EPOCH | -0.61 | -2.9 | -1.55 | -0.56 |
Differences from baseline (specified follow-up assessment minus baseline) in (HHV)-8 viral load. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | copies per 100uL (Median) |
|---|---|
| 12-month follow-up | |
| Phase II: VR-DA-EPOCH | 0 |
Differences from baseline (specified follow-up assessment minus baseline) in (HHV)-8 viral load. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | copies per 100uL (Median) | ||
|---|---|---|---|
| At treatment discontinuation | 6-month follow-up | 12-month follow-up | |
| Phase II: DA-R-EPOCH | 0 | 0 | 0 |
Differences from baseline (specified follow-up assessment minus baseline) in HIV viral load. Undetectable viral load results were treated as 0 values. (NCT01193842)
Timeframe: Baseline up to 12 months
| Intervention | median change in copies per mL (Median) | |||
|---|---|---|---|---|
| End of Cycle 2 | At treatment discontinuation | 6-month follow-up | 12-month follow-up | |
| Phase II: DA-R-EPOCH | -25 | -22.5 | -18 | -20 |
| Phase II: VR-DA-EPOCH | -20 | -87 | -20 | 0 |
The percentage of participants with AEs and their worst severity will be tabulated for each treatment arm. If a participant has more than one AE, the most severe AE is analyzed. All adverse events will be assessed by the investigator from the first dose of protocol therapy through the post-treatment discontinuation visit. Participants are planned to be treated for a total of 6 cycles (21 day cycle length), or roughly 4 months. After this evaluation, assessment and reporting of AEs will only be required for all grade 5 AEs and any serious AE (SAE) that the investigator considers related to protocol therapy. (NCT01193842)
Timeframe: Up to 5 years
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Death | Life-threatening | Severe | Moderate | Mild | |
| Phase II: DA-R-EPOCH | 20.0 | 28.9 | 31.1 | 17.8 | 0 |
| Phase II: VR-DA-EPOCH | 28.9 | 37.8 | 20.0 | 8.9 | 2.2 |
Serial plasma samples for pharmacokinetic analysis were collected at 24-48, 48-72, and 72-96 hours after the start of the first chemotherapy infusion. Doxorubicin, etoposide, and vincristine concentrations were determined using a validated liquid chromatography-tandem mass spectrometry method. The clearance was determined by dividing the drug-infusion rate by the steady-state concentrations, which was the average of the three time points. (NCT01193842)
Timeframe: 24-48, 48-72, and 72-96 hours after the start of the first chemotherapy infusion
| Intervention | Liter/hour (Mean) | ||
|---|---|---|---|
| Doxorubicin | Etoposide | Vincristine | |
| Phase I: VR-DA-EPOCH, Dose Level 1 | 78.6 | 3.0 | 22.4 |
| Phase I: VR-DA-EPOCH, Dose Level 2 | 76.0 | 2.4 | 16.8 |
The percentage of participants whose best tumor response is complete response (CR) or partial response (PR). Based on clinical, radiologic (CT), and pathologic criteria, CR requires 1) complete disappearance of all detectable disease and disease-related symptoms if present before therapy, 2) bone marrow aspirate and biopsy to confirm a CR if initially positive or if clinically indicated by new abnormalities in the peripheral blood counts or blood smear, 3) negative PET results, depending on typically, variably, or unknown pre-treatment FDG status, and 4) spleen and/or liver, if considered to be enlarged before therapy on physical examination or CT scan, not being palpable on physical examination and considered normal size by imaging studies, and nodules related to lymphoma disappeared. PR includes 1) ≥50% decrease in sum of product of diameters (SPD), 2) no increase in size of nodes, liver, or spleen, 3) splenic/hepatic nodules regressed by ≥ 50% SPD, 4) no new sites of disease (NCT01193842)
Timeframe: Up to 2 years post treatment
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Complete response | Partial Response | |
| Phase I: Arm C (VR-CHOP) Dose Level 1 | 100 | 0 |
| Phase I: VR-DA-EPOCH, Dose Level 1 | 83.3 | 16.7 |
| Phase I: VR-DA-EPOCH, Dose Level 2 | 83.3 | 16.7 |
6 reviews available for prednisone and B Virus Infection
| Article | Year |
|---|---|
HIV-negative, HHV-8-unrelated primary effusion lymphoma-like lymphoma: report of two cases.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic | 2010 |
Primary effusion lymphoma.
Topics: Anti-Retroviral Agents; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cyclophospham | 2007 |
Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors.
Topics: Adult; AIDS-Related Opportunistic Infections; Antineoplastic Combined Chemotherapy Protocols; Bleomy | 1995 |
Primary intracerebral Hodgkin's disease: report of a case with Epstein-Barr virus association and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain; Brain Neoplasms; Combined | 1999 |
A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bleomycin; | 2001 |
Lymphoproliferative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression.
Topics: Actuarial Analysis; Antilymphocyte Serum; Azathioprine; Carcinoma; Cyclosporine; Graft Survival; Her | 1992 |
3 trials available for prednisone and B Virus Infection
| Article | Year |
|---|---|
Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial).
Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; | 2020 |
Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors.
Topics: Adult; AIDS-Related Opportunistic Infections; Antineoplastic Combined Chemotherapy Protocols; Bleomy | 1995 |
Prednisone therapy is not associated with increased risk of herpetic infections in patients infected with human immunodeficiency virus.
Topics: AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Chickenpox; Cytomegalovirus Infections; | 1996 |
35 other studies available for prednisone and B Virus Infection
| Article | Year |
|---|---|
Extracavitary primary effusion lymphoma initially presenting with hemophagocytic lymphohistocytosis.
Topics: Adrenal Cortex Hormones; Adult; Anti-HIV Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2014 |
Human Herpesvirus Type 8-positive Multicentric Castleman Disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Castleman Disea | 2016 |
Human Herpesvirus 8-Unrelated Primary Effusion Lymphoma-Like Lymphoma in an Elderly Korean Patient with a Good Response to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone.
Topics: Age Factors; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Prot | 2017 |
Intracavitary cidofovir for human herpes virus-8-associated primary effusion lymphoma in an HIV-negative patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Cidofovir; Cyclophosphamide; | 2010 |
A case of successful management of HHV-8⁺, EBV⁺ germinotropic lymphoproliferative disorder (GLD).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Germinal Center | 2012 |
Lymphocytic interstitial pneumonitis associated with Epstein-Barr virus in Systemic Lupus Erythematosus and Sjögren's Syndrome. Complete remission with corticosteriod and cyclophosphamide.
Topics: Cyclophosphamide; Female; Glucocorticoids; Herpesviridae Infections; Herpesvirus 4, Human; Humans; I | 2002 |
KSHV- and EBV-associated germinotropic lymphoproliferative disorder.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Clone Cells; Cyclophosphamide; Doxorubicin; | 2002 |
HHV8-related non-Hodgkin's lymphoma of the spermatic cord in a patient with HIV-associated multicentric Castleman disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Castleman Dis | 2003 |
Nonnecrotizing herpetic retinopathies masquerading as severe posterior uveitis.
Topics: Acyclovir; Adult; Aged; Aged, 80 and over; Antibodies, Viral; Antiviral Agents; Aqueous Humor; Diagn | 2003 |
NECROTIZING TOXOPLASMIC ENCEPHALITIS AND HERPETIC PNEUMONIA COMPLICATING TREATED HODGKIN'S DISEASE. REPORT OF A CASE.
Topics: Alkylating Agents; Antineoplastic Agents; Cyclophosphamide; Encephalitis; Herpesviridae Infections; | 1965 |
Rapidly progressive human herpesvirus 8-associated solid anaplastic lymphoma in a patient with AIDS--associated Kaposi sarcoma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Pro | 2003 |
KSHV/HHV8-associated lymphoma simulating anaplastic large cell lymphoma.
Topics: AIDS-Related Opportunistic Infections; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derive | 2004 |
Posttransplant lymphoma--a single-center experience of 500 liver transplantations.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2004 |
[Arguments favouring the pharmacotherapy of Bells' palsy].
Topics: Acyclovir; Anti-Inflammatory Agents; Antiviral Agents; Bell Palsy; Herpesviridae Infections; Humans; | 2005 |
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy.
Topics: Adolescent; Adult; Cadaver; Cyclosporins; Female; Heart Transplantation; Herpesviridae Infections; H | 1984 |
Studies on long-term T-cell-mediated immunity to Epstein-BArr virus in immunosuppressed renal allograft recipients.
Topics: Azathioprine; Cyclosporins; Herpesviridae Infections; Herpesvirus 4, Human; Humans; Kidney Transplan | 1981 |
Acute cranial polyneuritis with vertigo after stapedectomy.
Topics: Adult; Cranial Nerve Diseases; Female; Herpesviridae Infections; Humans; Male; Middle Aged; Polyneur | 1983 |
Localized, late-onset, high-grade lymphoma following bone marrow transplantation: response to combination chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modalit | 1994 |
Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Base Sequ | 1995 |
Synchronous presentation of Epstein-Barr virus-associated Hodgkin's disease and adult T-cell leukemia/lymphoma (ATLL) in a patient from an endemic area of ATLL.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazi | 1995 |
Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; B-Lymphoc | 1996 |
Hodgkin's disease after cardiac transplant: a report of two cases.
Topics: Adult; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Chlorambuci | 1996 |
Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children.
Topics: Adolescent; Age Factors; Antiviral Agents; Azathioprine; Child; Child, Preschool; Cyclosporine; Foll | 1997 |
Human herpes virus-6 encephalitis after bone marrow transplantation: successful treatment with ganciclovir.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation | 1997 |
The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver transplant recipients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Herpes | 1997 |
Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center.
Topics: Adult; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubi | 2000 |
Recurrent erythema multiforme and Herpes genitalis (type 2).
Topics: Adolescent; Erythema Multiforme; Herpesviridae Infections; Humans; Male; Mucous Membrane; Penis; Pre | 1975 |
Effect of herpesvirus infections on T-lymphocyte subpopulations and blastogenic responses in renal transplant recipients receiving cyclosporine.
Topics: Adolescent; Adult; Antigens, Differentiation, T-Lymphocyte; Antigens, Surface; Cyclosporins; Cytomeg | 1986 |
Herpes B virus encephalomyelitis presenting as ophthalmic zoster. A possible latent infection reactivated.
Topics: Animals; Antibodies; Aphasia; Ataxia; Cerebrospinal Fluid Proteins; Cytarabine; Diagnosis, Different | 1973 |
Clinically evident, non-terminal infections with herpesviruses and the wart virus in immunosuppressed renal allograft recipients.
Topics: Adolescent; Adult; Azathioprine; Child; Complement Fixation Tests; Cytomegalovirus Infections; Femal | 1970 |
[Herpes gestations].
Topics: Adult; Female; Herpesviridae Infections; Humans; Infant Mortality; Infant, Newborn; Postpartum Perio | 1971 |
Fatalities during remission of childhood leukemia.
Topics: Adolescent; Autopsy; Child; Child, Preschool; Cytomegalovirus; Daunorubicin; Female; Herpesviridae I | 1972 |
Herpesviruses in renal transplant patients.
Topics: Agglutination Tests; Antibodies, Viral; Azathioprine; Cell Line; Complement Fixation Tests; Culture | 1973 |
Fatal herpes hepatitis associated with pemphigus vulgaris and steroids in an adult.
Topics: Female; Hepatitis A; Herpes Simplex; Herpesviridae; Herpesviridae Infections; Humans; Liver; Microsc | 1974 |
Cutaneous Herpesvirus hominis (type 2) infection after renal transplantation.
Topics: Acute Disease; Adult; Antibodies, Viral; Azathioprine; Biopsy; Herpesviridae Infections; Humans; Kid | 1974 |